Key Takeaway
When comparing Saxenda vs alternatives, the key differences come down to weight loss magnitude, dosing frequency, mechanism of action, and cost....
When comparing Saxenda vs alternatives, the key differences come down to weight loss magnitude, dosing frequency, mechanism of action, and cost. Saxenda (liraglutide 3.0 mg) produces average weight loss of 8% over one year, which is effective but trails newer options like Wegovy (15%) and Zepbound (20%). Your best choice depends on your insurance coverage, tolerance for injections, medical history, and weight loss goals.
Key Takeaways
- The STEP 8 trial[1] directly compared Saxenda to Wegovy and found semaglutide produced 2.4 times more weight loss (15.8% vs 6.4%) over 68 weeks .
- Saxenda requires daily injections while Wegovy and Zepbound are weekly, which affects adherence for many patients.
- Tirzepatide (Zepbound/Mounjaro) uses a dual GIP/GLP-1 mechanism that produces the highest weight loss of any approved medication at approximately 20% .
- Rybelsus (oral semaglutide) offers a pill alternative to injections, though with lower weight loss efficacy than injectable semaglutide.
- Insurance coverage varies dramatically between medications, and Saxenda sometimes has better coverage than newer alternatives.
- Your provider at FormBlends can help match you with the medication that fits your health profile and goals.
Head-to-Head Comparison Table
| Feature | Saxenda | Wegovy | Zepbound | Rybelsus | Contrave |
|---|---|---|---|---|---|
| Generic name | Liraglutide | Semaglutide | Tirzepatide | Semaglutide (oral) | Naltrexone/Bupropion |
| Mechanism | GLP-1 agonist | GLP-1 agonist | GLP-1 + GIP dual agonist | GLP-1 agonist | Opioid antagonist + antidepressant |
| Administration | Daily injection | Weekly injection | Weekly injection | Daily oral pill | Twice-daily oral pill |
| Avg weight loss | ~8% | ~15% | ~20% | ~6-10% | ~5-6% |
| FDA approved for weight loss | Yes (2014) | Yes (2021) | Yes (2023) | No (off-label) | Yes (2014) |
| Retail cost/month | ~$1,350-1,500 | ~$1,300-1,400 | ~$1,000-1,100 | ~$900-1,000 | ~$300-500 |
| Escalation period | 5 weeks | 16-20 weeks | 20+ weeks | 8 weeks | 4 weeks |
Saxenda vs. Wegovy (Semaglutide)
This is the most direct comparison because both are pure GLP-1 receptor agonists. The STEP 8 trial (published in JAMA, 2022) randomized 338 adults to either semaglutide 2.4 mg weekly or liraglutide 3.0 mg daily for 68 weeks. The results were definitive:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
- Semaglutide group: 15.8% mean body weight loss[3]
- Liraglutide group: 6.4% mean body weight loss
- Proportion achieving 10%+ weight loss: 70.9% (semaglutide) vs. 25.6% (liraglutide)
- Proportion achieving 20%+ weight loss: 38.5% (semaglutide) vs. 6.0% (liraglutide)
The superiority of semaglutide comes from its higher binding affinity to the GLP-1 receptor and its dramatically longer half-life (7 days vs. 13 hours for liraglutide). This means more sustained receptor activation and stronger appetite suppression around the clock.
When Saxenda Might Still Be the Better Choice
- Insurance coverage. Some plans cover Saxenda (especially if liraglutide has been on formulary since 2014) but haven't yet added Wegovy.
- Supply availability. Wegovy has experienced intermittent supply shortages since its launch. Saxenda supply has been more stable.
- Preference for daily dosing. Some patients prefer the control of a daily injection that wears off in hours rather than a weekly injection whose effects last for days.
- Dose flexibility. If you experience side effects, Saxenda's daily dosing allows for more granular adjustments (skipping a day, briefly stepping down to a lower dose).
- Prior response. Patients who responded well to Victoza (liraglutide 1.2 or 1.8 mg for diabetes) are likely good candidates for the weight management dose.
Saxenda vs. Zepbound (Tirzepatide)
Zepbound represents the newest class of weight loss medication: a dual GIP/GLP-1 receptor agonist. By activating both incretin receptors simultaneously, tirzepatide produces the most dramatic weight loss of any approved medication.
In the SURMOUNT-1 trial[2], patients on the highest tirzepatide dose (15 mg weekly) lost an average of 22.5% of their body weight over 72 weeks. At the lowest dose (5 mg), they still lost 15% . Even tirzepatide's minimum dose produces nearly double the weight loss of Saxenda's maximum dose.
The mechanism difference is significant. GIP (glucose-dependent insulinotropic polypeptide) acts on fat tissue to improve fat storage and breakdown, reduces inflammation, and may have direct effects on brain appetite centers that complement GLP-1 signaling .
Practical Differences
- Weight loss magnitude: Zepbound produces roughly 2.5 to 3 times the weight loss of Saxenda.
- Injection frequency: Weekly (Zepbound) vs daily (Saxenda). Most patients strongly prefer weekly dosing.
- Side effect profile: Both cause similar GI side effects (nausea, diarrhea, constipation). Zepbound may cause more nausea during escalation due to dual receptor activation.
- Cost: Zepbound is slightly less expensive at retail (approximately $1,000 to $1,100/month) compared to Saxenda ($1,350 to $1,500/month) $1,000-$1,200/mo (brand) Contact provider for current pricing.
- Track record: Saxenda has over 10 years of post-market safety data. Zepbound was approved in late 2023 and has roughly 2 years of real-world experience.
Saxenda vs. Rybelsus (Oral Semaglutide)
Rybelsus is an oral form of semaglutide approved for type 2 diabetes, increasingly used off-label for weight management. It appeals to patients who want the GLP-1 mechanism without injections.
But oral semaglutide has significantly lower bioavailability than injectable semaglutide. Only about 1% of the oral dose is absorbed, which is why Rybelsus doses (7 to 14 mg) are much higher numerically than Wegovy doses (up to 2.4 mg) . The weight loss efficacy of oral semaglutide 14 mg falls somewhere between Saxenda and Wegovy, with studies showing approximately 6 to 10% body weight reduction depending on the population studied.
Practical Comparison
| Factor | Saxenda | Rybelsus |
|---|---|---|
| Route | Subcutaneous injection | Oral tablet |
| Frequency | Daily | Daily |
| Weight loss | ~8% | ~6-10% |
| FDA weight loss approval | Yes | No (off-label for weight loss) |
| Dosing restrictions | None (inject anytime) | Must take on empty stomach with 4 oz water, wait 30 min before eating |
| Cost | ~$1,350-1,500/month | ~$900-1,000/month |
Rybelsus's strict dosing requirements (empty stomach, small sip of water, 30-minute wait before food or other medications) can be inconvenient but are necessary for absorption. Patients who dislike injections may find this trade-off worthwhile.
Saxenda vs. Contrave (Naltrexone/Bupropion)
Contrave works through an entirely different mechanism. It combines naltrexone (an opioid receptor antagonist) with bupropion (an antidepressant) to reduce food cravings and the reward value of eating. It doesn't affect GLP-1 receptors or gastric emptying.
In the COR-I trial, Contrave produced an average weight loss of 5.4% over 56 weeks, compared to 1.3% for placebo . This is roughly two-thirds the efficacy of Saxenda.
Where Contrave May Be Preferred
- Cost. At $300 to $500 per month, Contrave is significantly cheaper than any GLP-1 medication Contact provider for current pricing.
- No injections. Contrave is a twice-daily pill, which many patients prefer.
- Emotional eating. Because bupropion affects dopamine and norepinephrine, Contrave may be particularly effective for patients whose weight gain is driven by emotional or reward-based eating rather than physiological hunger.
- Depression co-occurrence. Patients with concurrent depression may benefit from bupropion's mood-improving effects alongside weight loss.
Where Saxenda Is Superior
- Weight loss magnitude. Saxenda produces approximately 50% more weight loss than Contrave on average.
- Blood sugar benefits. GLP-1 agonism provides meaningful improvements in glucose metabolism that Contrave doesn't.
- Cardiovascular data. Liraglutide has cardiovascular outcome data (LEADER trial) showing reduced major cardiac events in type 2 diabetes patients .
Saxenda vs. Compounded Semaglutide
Compounded semaglutide has emerged as a lower-cost alternative to branded Wegovy and Ozempic. These are semaglutide preparations made by compounding pharmacies, typically at a fraction of the branded drug price.
Comparing compounded semaglutide to Saxenda is straightforward on efficacy: semaglutide (even compounded) produces more weight loss than liraglutide. The key considerations are:
- Cost advantage: Compounded semaglutide through programs like FormBlends can cost $300 to $500 per month, far less than branded Saxenda.
- Regulatory status: Compounded semaglutide is legal under FDA compounding rules when there's a drug shortage. the regulatory space is evolving, so availability may change .
- Quality variability: Compounding pharmacy quality varies. Work only with providers who source from 503B-registered facilities with third-party testing.
For most patients, compounded semaglutide offers better weight loss at a lower price point than Saxenda, making it a strong alternative to consider.
Decision Framework: Which Is Right for You?
| If Your Priority Is... | Consider... | Why |
|---|---|---|
| Maximum weight loss | Zepbound (tirzepatide) | Highest efficacy at ~20% body weight loss |
| Best balance of efficacy and data | Wegovy (semaglutide) | Strong weight loss (~15%) with extensive safety data |
| Avoiding injections entirely | Contrave or Rybelsus | Oral medications with no needles required |
| Lowest cost | Compounded semaglutide or Contrave | $300-500/month vs $1,000-1,500 for branded GLP-1s |
| Proven long-term safety record | Saxenda | On market since 2014 with 10+ years of real-world data |
| Daily dose control | Saxenda | Effects wear off in hours. easy to pause or adjust |
| Blood sugar management too | Wegovy, Zepbound, or Saxenda | All GLP-1 medications improve glucose metabolism |
Frequently Asked Questions
Is Saxenda still worth taking with newer options available?
For some patients, yes. If your insurance covers Saxenda but not Wegovy or Zepbound, if you prefer daily dosing, or if you have responded well to liraglutide in the past, Saxenda remains a reasonable choice. It produces meaningful weight loss (8% average) that significantly exceeds diet and exercise alone (2 to 3%).
Can I switch from Saxenda to Wegovy?
Yes. Many patients start on Saxenda and later transition to Wegovy for greater weight loss. There's no required washout period. Your provider will typically start Wegovy's dose escalation from the beginning (0.25 mg weekly) even if you were on full-dose Saxenda, though some may start at a slightly higher dose based on your tolerance history.
Why does Saxenda cost more than Zepbound?
Pricing in the pharmaceutical market is complex and doesn't always reflect efficacy. Saxenda's pricing was set in 2014 when it was the only GLP-1 weight loss option. Eli Lilly priced Zepbound more aggressively to capture market share. Actual out-of-pocket costs depend heavily on your insurance plan and available savings programs Contact provider for current pricing $1,000-$1,200/mo (brand).
Is Contrave safer than Saxenda?
Both medications have distinct safety profiles. Contrave carries a boxed warning for suicidal ideation (due to bupropion) and is contraindicated in patients with seizure disorders, eating disorders, or those taking opioids. Saxenda carries a boxed warning for thyroid C-cell tumors (observed in rodents). Neither medication is inherently "safer." The right choice depends on your specific health profile .
Can I combine Saxenda with other weight loss medications?
Saxenda shouldn't be combined with other GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound, Victoza). Combining Saxenda with non-GLP-1 medications like phentermine or Contrave is sometimes done off-label by weight loss specialists, but this requires careful medical supervision and isn't FDA-approved .
What if I can't afford any branded medication?
Compounded semaglutide through telehealth programs like FormBlends offers GLP-1 therapy at a fraction of branded drug prices, with the added benefit of semaglutide's superior efficacy over liraglutide. Generic liraglutide may also become available as Saxenda's patents expire, though timelines vary by market.
Medical References
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2023;327(2):138-150. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. [PubMed | ClinicalTrials.gov | DOI]
Find Your Best Weight Loss Medication
Choosing between Saxenda and its alternatives is a medical decision that should be guided by your unique health profile, insurance situation, and weight loss goals. At FormBlends, our physicians specialize in GLP-1 therapy and can walk you through every option to find your best fit. Schedule a consultation to get a personalized recommendation based on your specific needs.